{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:50:24Z","timestamp":1793875824216,"version":"4.7.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background &amp; aims<\/jats:title>\n                    <jats:p>Primary Sclerosing Cholangitis (PSC) is a chronic cholestatic liver condition that is closely associated with inflammatory bowel disease (IBD). PSC is associated with substantial long-term hepatobiliary morbidity, including an increased risk of cholangiocarcinoma. Reported prevalence and incidence estimates of PSC vary widely across different populations and study designs. This meta-analysis aims to provide an updated estimate of the prevalence of PSC in the general and IBD populations, and PSC incidence in the general population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of MEDLINE (Ovid) and Embase from inception to October 20, 2025, for population- or cohort-based studies reporting PSC prevalence or incidence was performed. Seventy-four studies met the inclusion criteria. Random-effects meta-analyses were performed to pool prevalence and incidence estimates. Subgroup analyses, meta-regression, and sensitivity analyses were conducted to assess robustness and sources of heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seventeen studies including 196,635,709 individuals showed a pooled overall PSC prevalence of 8.06 per 100,000 (95% CI 4.75\u201313.36) in the general population. Among 516,548 patients with IBD in thirty-four studies, pooled PSC prevalence was 15.2 per 1,000 (95% CI 10.7\u201321.7). PSC prevalence was higher in ulcerative colitis (20.6 per 1,000) than in Crohn\u2019s disease (10.2 per 1,000). Using Crohn\u2019s disease as the reference group, ulcerative colitis was associated with higher odds of PSC (OR 1.787, 95% CI 1.066\u20132.996,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.028). Thirteen studies reported a pooled incidence of PSC in the general population of 0.892 per 100,000 person-years (95% CI 0.705\u20131.130).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This meta-analysis provides an updated synthesis of PSC epidemiology, extending prior work by incorporating detailed subgroup analyses across IBD phenotype, PSC subtype, geographic region, socioeconomic context, diagnostic modality, case-ascertainment method, and time period, which are dimensions not comprehensively addressed in previous meta-analyses. PSC remains a rare disease in the general population but is substantially more prevalent among individuals with IBD. Marked geographic and methodological heterogeneity, with notable underrepresentation of data from lower-SDI regions and the African Region, underscores the need for standardized case definitions and improved epidemiological surveillance across diverse settings. Given the markedly increased risk of cholangiocarcinoma in PSC, these findings highlight the clinical importance of recognizing PSC in higher-risk IBD populations and provide an epidemiological foundation for future studies evaluating risk stratification, early detection, and surveillance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12072-026-11127-y","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T06:55:52Z","timestamp":1783752952000},"page":"1463-1478","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Epidemiology of primary sclerosing cholangitis in general and IBD populations: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"20","author":[{"given":"Glenn Jun Kit","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asvin","family":"Selvakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas Yang Yuxu","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mako","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan Yanzhe","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedix Kuan Loon","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Tung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apoorva N","family":"Sasikumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley Huey Shin","family":"Bong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan Kai Jun","family":"Tham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia Hao","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice Xiang-Xuan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Wentworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Mook","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Assis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Nah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0157-6066","authenticated-orcid":false,"given":"Vincent L.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"issue":"1","key":"11127_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.14218\/JCTH.2013.00021","volume":"2","author":"M Saadi","year":"2014","unstructured":"Saadi M, Yu C, Othman MO. A Review of the Challenges Associated with the Diagnosis and Therapy of Primary Sclerosing Cholangitis. J Clin Transl Hepatol. 2014;2(1):45\u201352. https:\/\/doi.org\/10.14218\/JCTH.2013.00021","journal-title":"J Clin Transl Hepatol"},{"issue":"2","key":"11127_CR2","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/hep.32771","volume":"77","author":"CL Bowlus","year":"2023","unstructured":"Bowlus CL, Arriv\u00e9 L, Bergquist A, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2023;77(2):659\u2013702. https:\/\/doi.org\/10.1002\/hep.32771","journal-title":"Hepatology"},{"issue":"7","key":"11127_CR3","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1038\/s12276-023-01042-9","volume":"55","author":"YS Kim","year":"2023","unstructured":"Kim YS, Hurley EH, Park Y, Ko S. Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD): a condition exemplifying the crosstalk of the gut-liver axis. Exp Mol Med. 2023;55(7):1380\u20131387. https:\/\/doi.org\/10.1038\/s12276-023-01042-9","journal-title":"Exp Mol Med"},{"issue":"6","key":"11127_CR4","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.3748\/wjg.v21.i6.1956","volume":"21","author":"AB de Vries","year":"2015","unstructured":"de Vries AB, Janse M, Blokzijl H, Weersma RK. Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. World J Gastroenterol. 2015;21(6):1956\u20131971. https:\/\/doi.org\/10.3748\/wjg.v21.i6.1956","journal-title":"World J Gastroenterol"},{"issue":"2","key":"11127_CR5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s00534-010-0319-8","volume":"18","author":"H Sano","year":"2011","unstructured":"Sano H, Nakazawa T, Ando T, et al. Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis. J Hepatobiliary Pancreat Sci. 2011;18(2):154\u2013161. https:\/\/doi.org\/10.1007\/s00534-010-0319-8","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"2","key":"11127_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.5946\/ce.2020.019-IDEN","volume":"54","author":"P Bhat","year":"2021","unstructured":"Bhat P, Aabakken L. Role of endoscopy in primary sclerosing cholangitis. Clin Endosc. 2021;54(2):193\u2013201. https:\/\/doi.org\/10.5946\/ce.2020.019-IDEN","journal-title":"Clin Endosc"},{"key":"11127_CR7","doi-asserted-by":"publisher","first-page":"1544601","DOI":"10.3389\/fmed.2025.1544601","volume":"12","author":"H Yang","year":"2025","unstructured":"Yang H, Zhen J, Huang X, et al. Current status of pharmacotherapy for primary sclerosing cholangitis. Front Med (Lausanne). 2025;12:1544601. https:\/\/doi.org\/10.3389\/fmed.2025.1544601","journal-title":"Front Med (Lausanne)."},{"issue":"10","key":"11127_CR8","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1111\/liv.15007","volume":"41","author":"TI Mehta","year":"2021","unstructured":"Mehta TI, Weissman S, Fung BM, Sotiriadis J, Lindor KD, Tabibian JH. Global incidence, prevalence and features of primary sclerosing cholangitis: a systematic review and meta-analysis. Liver Int. 2021;41(10):2418\u20132426. https:\/\/doi.org\/10.1111\/liv.15007","journal-title":"Liver Int"},{"key":"11127_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020;372: n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"11127_CR10","doi-asserted-by":"publisher","unstructured":"Schwarzer, G., R\u00fccker, G. (2022). Meta-Analysis of Proportions. In: Evangelou, E., Veroniki, A.A. (eds) Meta-Research. Methods in Molecular Biology, vol 2345. Humana, New York, NY. https:\/\/doi.org\/10.1007\/978-1-0716-1566-9_10","DOI":"10.1007\/978-1-0716-1566-9_10"},{"issue":"4","key":"11127_CR11","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1214\/aoms\/1177729756","volume":"21","author":"MF Freeman","year":"1950","unstructured":"Freeman MF, Tukey JW. Transformations Related to the Angular and the Square Root. Ann Math Statist. 1950;21(4):607\u2013611","journal-title":"Ann. Math. Statist."},{"issue":"3","key":"11127_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. \u201cConducting meta-analyses in R with the Metafor package.\u201d J Stat Softw. 2010;36(3):1\u201348. https:\/\/doi.org\/10.18637\/jss.v036.i03","journal-title":"J Stat Softw"},{"key":"11127_CR13","unstructured":"West SL GG, Mansfield AJ, et al. Comparative Effectiveness Review Methods: Clinical Heterogeneity. Rockville (MD): Agency for Healthcare Research and Quality (US); 2010."},{"key":"11127_CR14","unstructured":"Organization WH. World Health Statistics 2024. 2024. 21 May 2024. Accessed 25 December 2025. https:\/\/www.who.int\/data\/gho\/publications\/world-health-statistics"},{"key":"11127_CR15","unstructured":"Institute for Health Metrics and Evaluation. Sociodemographic Index Groupings by Geography (2016 Values). Global Burden of Disease Study, 2020."},{"issue":"6","key":"11127_CR16","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gut.2005.082909","volume":"55","author":"J Satsangi","year":"2006","unstructured":"Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):749\u2013753. https:\/\/doi.org\/10.1136\/gut.2005.082909","journal-title":"Gut"},{"key":"11127_CR17","doi-asserted-by":"crossref","unstructured":"Munn Z MS, Lisy K, Riitano D, Tufanaru C. Chapter 5: Systematic reviews of prevalence and incidence. In: Aromataris E, Munn Z (Editors). JBI Manual for Evidence Synthesis. JBI, 2020.","DOI":"10.46658\/JBIRM-17-05"},{"issue":"6","key":"11127_CR18","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1053\/j.gastro.2021.08.032","volume":"161","author":"B Barberio","year":"2021","unstructured":"Barberio B, Massimi D, Cazzagon N, Zingone F, Ford AC, Savarino EV. Prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease: a systematic review and meta-analysis. Gastroenterology. 2021;161(6):1865\u20131877. https:\/\/doi.org\/10.1053\/j.gastro.2021.08.032","journal-title":"Gastroenterology"},{"issue":"11","key":"11127_CR19","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1093\/ibd\/izad276","volume":"30","author":"J Cooper","year":"2024","unstructured":"Cooper J, Markovinovic A, Coward S, et al. Incidence and prevalence of primary sclerosing cholangitis: a meta-analysis of population-based studies. Inflamm Bowel Dis. 2024;30(11):2019\u20132026. https:\/\/doi.org\/10.1093\/ibd\/izad276","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"11127_CR20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.cgh.2017.07.023","volume":"16","author":"N Krugliak Cleveland","year":"2018","unstructured":"Krugliak Cleveland N, Rubin DT, Hart J, et al. Patients with ulcerative colitis and primary sclerosing cholangitis frequently have subclinical inflammation in the proximal colon. Clin Gastroenterol Hepatol. 2018;16(1):68\u201374. https:\/\/doi.org\/10.1016\/j.cgh.2017.07.023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"11127_CR21","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1136\/gutjnl-2015-310500","volume":"66","author":"M Kummen","year":"2017","unstructured":"Kummen M, Holm K, Anmarkrud JA, et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut. 2017;66(4):611\u2013619. https:\/\/doi.org\/10.1136\/gutjnl-2015-310500","journal-title":"Gut"},{"issue":"4","key":"11127_CR22","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1053\/j.gastro.2008.01.042","volume":"134","author":"E Bj\u00f6rnsson","year":"2008","unstructured":"Bj\u00f6rnsson E, Olsson R, Bergquist A, et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology. 2008;134(4):975\u2013980. https:\/\/doi.org\/10.1053\/j.gastro.2008.01.042","journal-title":"Gastroenterology"},{"issue":"10114","key":"11127_CR23","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769\u20132778. https:\/\/doi.org\/10.1016\/S0140-6736(17)32448-0","journal-title":"Lancet"},{"issue":"3","key":"11127_CR24","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/ajg.2009.727","volume":"105","author":"A Kornbluth","year":"2010","unstructured":"Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105(3):501\u2013524. https:\/\/doi.org\/10.1038\/ajg.2009.727","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"11127_CR25","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","volume":"4","author":"A Dignass","year":"2010","unstructured":"Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease: current management. J Crohns Colitis. 2010;4(1):28\u201362. https:\/\/doi.org\/10.1016\/j.crohns.2009.12.002","journal-title":"J Crohns Colitis"},{"issue":"6","key":"11127_CR26","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.14309\/ajg.0000000000003463","volume":"120","author":"DT Rubin","year":"2025","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, Barnes EL, Long MD. ACG clinical guideline update: ulcerative colitis in adults. Am J Gastroenterol. 2025;120(6):1187\u20131224. https:\/\/doi.org\/10.14309\/ajg.0000000000003463","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"11127_CR27","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570\u20131583. https:\/\/doi.org\/10.1053\/j.gastro.2020.12.031","journal-title":"Gastroenterology"},{"issue":"4","key":"11127_CR28","first-page":"277","volume":"11","author":"J Ong","year":"2018","unstructured":"Ong J, Bath MF, Swift C, Al-Naeeb Y. Does colectomy affect the progression of primary sclerosing cholangitis? A systematic review and meta-analysis. Gastroenterol Hepatol Bed Bench. 2018;11(4):277\u2013283","journal-title":"Gastroenterol Hepatol Bed Bench"},{"issue":"2","key":"11127_CR29","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/apt.14393","volume":"47","author":"C Nordenvall","year":"2018","unstructured":"Nordenvall C, Ol\u00e9n O, Nilsson PJ, et al. Colectomy prior to diagnosis of primary sclerosing cholangitis is associated with improved prognosis in a nationwide cohort study of 2594 PSC-IBD patients. Aliment Pharmacol Ther. 2018;47(2):238\u2013245. https:\/\/doi.org\/10.1111\/apt.14393","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"11127_CR30","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/ng.2616","volume":"45","author":"JZ Liu","year":"2013","unstructured":"Liu JZ, Hov JR, Folseraas T, et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet. 2013;45(6):670\u2013675. https:\/\/doi.org\/10.1038\/ng.2616","journal-title":"Nat Genet"},{"issue":"10","key":"11127_CR31","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1136\/gutjnl-2015-311004","volume":"65","author":"J Sabino","year":"2016","unstructured":"Sabino J, Vieira-Silva S, Machiels K, et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut. 2016;65(10):1681\u20131689. https:\/\/doi.org\/10.1136\/gutjnl-2015-311004","journal-title":"Gut"},{"issue":"6","key":"11127_CR32","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","volume":"67","author":"TH Karlsen","year":"2017","unstructured":"Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis - a comprehensive review. J Hepatol. 2017;67(6):1298\u20131323. https:\/\/doi.org\/10.1016\/j.jhep.2017.07.022","journal-title":"J Hepatol"},{"issue":"5","key":"11127_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0322479","volume":"20","author":"M Olfatifar","year":"2040","unstructured":"Olfatifar M, Rajabnia M, Sadeghi A, et al. The epidemiological trends and projected future of primary sclerosing cholangitis by 2040: an updated meta-analysis and modeling study. PLoS ONE. 2040;20(5): e0322479. https:\/\/doi.org\/10.1371\/journal.pone.0322479","journal-title":"PLoS ONE"},{"key":"11127_CR34","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JA Sterne","year":"2011","unstructured":"Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002. https:\/\/doi.org\/10.1136\/bmj.d4002","journal-title":"BMJ"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11127-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-026-11127-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-026-11127-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:18:38Z","timestamp":1792271918000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-026-11127-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["11127"],"URL":"https:\/\/doi.org\/10.1007\/s12072-026-11127-y","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"20 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BJW has received consulting fees from Ipsen and GSK and speaking fees from Ipsen. AG has received research support from Gilead Sciences, and consulting and advisory fees from Mirum Pharmaceuticals, Kezar Life Sciences, Ipsen Pharmaceuticals, RegCell, DrenBio, and Gilead Sciences. VLC received research grants from AstraZeneca, KOWA, and Ipsen, paid to University of Michigan.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and Istanbul. This study was exempt from IRB review as no confidential patient information was involved.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}